Challenger Ltd's sales of key annuity predicted by broker to fall

An investment bank has predicted that one of Challenger Ltd's (ASX:CGF) key annuity products will lose sales.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Challenger Ltd (ASX: CGF) is Australia's leading annuity provider, it has a dominant market share of existing and new annuities. It sells a variety of annuities with different offerings for different clients.

Today, broker Morgan Stanley has reduced projections for Challenger's Liquid Lifetime by 20% each year from January 2019, which equates to $200 million.

According to an article in the AFR, Daniel Toohey, an analyst at Morgan Stanley, believes that changes to social security rules will mean this particular type of annuity will see falling sales as it can't be restructured enough to provide social security benefits.

Of course, Challenger has more products than just the one that Morgan Stanley are referring to, liquid lifetime sales only represent 19% of the total annuity sales.

Indeed, a Challenger spokesman said "The Morgan Stanley report refers to our regular lifetime annuity, which is one of five products in our liquid lifetime range, which also includes enhanced and flexible lifetime options, CarePlus and Deferred Lifetime Annuities. We are confident the current DSS process will result in settings that are sustainable for a broad range of pooled lifetime products."

It's a function of the market to have some people negative about a business and some people positive about a business. Perhaps the loss of franking credits will make Challenger's annuities more attractive to retirees. It's hard to say.

Even if Challenger loses a smallish portion of its annuity sales it has a large tailwind of people hitting retirement age to drive its long-term annuity sales upwards.

Foolish takeaway

I believe that Challenger is the best finance stock on the ASX and has a very beneficial tailwind. It's currently trading at 16x FY19's estimated earnings, which I think is a reasonable price to pay for a growing business.

Motley Fool contributor Tristan Harrison owns shares of Challenger Limited. The Motley Fool Australia owns shares of and has recommended Challenger Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »